[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593964":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":27,"responsibleParty":44,"collaborators":24,"id":46,"slug":24,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":24,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":24,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":24,"overallStatus":65,"whyStopped":24,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DWP712 inj.","EXPERIMENTAL","The investigational product will be administered by a single intramuscular injection, and 4 U\u002F0.1 mL of the IP will be injected into a total of 5 sites, totaling 20 U\u002F0.5 mL.",[13],"Biological: DWP712 inj.",{"label":15,"type":16,"description":11,"interventionNames":17},"Botox® 100 Units","ACTIVE_COMPARATOR",[18],"Biological: Botox® 100 Units",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Clostridium botulinum Toxin",[9],null,{"type":21,"name":15,"description":22,"armGroupLabels":26,"otherNames":24},[15],[28],{"facility":29,"status":24,"city":30,"state":24,"zip":24,"country":31,"countryCode":24,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Chung-Ang University Hosptial","Seoul","South Korea",{"type":33,"coordinates":34},"Point",[35,36],126.9784,37.566,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":42,"phoneExt":24,"email":43},"Beom Joon Kim, MD, phD","CONTACT","+82262991525","beomjoon74@gmail.com",{"type":45,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100593964",false,"NCT07013279","Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines","A Double-blind, Randomized, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP712 Inj. in Subjects With Moderate to Severe Glabellar Lines","Inclusion Criteria:\n\n\\- Subjects with a facial wrinkle scale (FWS) score of ≥2 (moderate) for glabellar lines at maximum frown in the investigator's on-site assessment at screening\n\nExclusion Criteria:\n\n\\- Subjects with glabellar lines that cannot sufficiently be improved by physical attempts, e.g., glabellar lines not flattened by hand, in the judgment of the investigator",true,"ALL","19 Years","65 Years",{"count":57,"type":58},324,"ESTIMATED","INTERVENTIONAL",[61],"PHASE3","To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines",[64],"Glabellar Lines","NOT_YET_RECRUITING","2025-06-02",{"date":68,"type":69},"2025-06-10","ACTUAL",{"date":71,"type":58},"2025-07-15",{"date":73,"type":58},"2026-03-31",{"name":5,"class":6},1]